MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives
MEI Pharma (Nasdaq: MEIP) has announced the engagement of Oppenheimer & Co. Inc. as its exclusive financial advisor to assist in evaluating strategic alternatives. This move is part of the company's previously announced process to review potential options, with a focus on maximizing stockholder value. MEI Pharma emphasizes that there is no guarantee that this exploration will result in any agreements or successful transactions. The company plans to maintain discretion regarding the process and will only disclose developments if required legally or deemed appropriate by the Board of Directors.
MEI Pharma (Nasdaq: MEIP) ha annunciato il coinvolgimento di Oppenheimer & Co. Inc. come suo consulente finanziario esclusivo per assistere nella valutazione delle alternative strategiche. Questa mossa fa parte del processo precedentemente annunciato dall'azienda per esaminare le opzioni potenziali, con un focus su massimizzare il valore per gli azionisti. MEI Pharma sottolinea che non c'è alcuna garanzia che questa esplorazione porterà a contratti o transazioni di successo. L'azienda intende mantenere riservatezza riguardo al processo e divulgherà gli sviluppi solo se legalmente richiesto o ritenuto appropriato dal Consiglio di Amministrazione.
MEI Pharma (Nasdaq: MEIP) ha anunciado la contratación de Oppenheimer & Co. Inc. como su asesor financiero exclusivo para ayudar en la evaluación de alternativas estratégicas. Este movimiento es parte del proceso previamente anunciado por la compañía para revisar opciones potenciales, con un enfoque en maximizar el valor para los accionistas. MEI Pharma enfatiza que no hay garantía de que esta exploración resulte en acuerdos o transacciones exitosas. La compañía planea mantener la discreción respecto al proceso y solo revelará desarrollos si es legalmente requerido o considerado apropiado por la Junta Directiva.
MEI Pharma (나스닥: MEIP)는 Oppenheimer & Co. Inc.를 전략적 대안을 평가하는 데 도움을 주기 위한 전담 재무 자문으로 고용했다고 발표했습니다. 이번 조치는 주주 가치를 극대화하는 데 중점을 두고 잠재적 옵션을 검토하기 위한 회사의 이전 발표 프로세스의 일환입니다. MEI Pharma는 이번 탐색이 계약이나 성공적인 거래로 이어질 보장이 없다고 강조하고 있습니다. 회사는 이 과정에 대한 비밀을 유지할 계획이며, 법적으로 요구되거나 이사회에서 적절하다고 판단한 경우에만 개발 사항을 공개할 것입니다.
MEI Pharma (Nasdaq: MEIP) a annoncé l'engagement de Oppenheimer & Co. Inc. en tant que conseiller financier exclusif pour l'aider à évaluer des alternatives stratégiques. Ce mouvement fait partie du processus précédemment annoncé par la société pour examiner les options potentielles, en mettant l'accent sur la maximisation de la valeur pour les actionnaires. MEI Pharma souligne qu'il n'y a aucune garantie que cette exploration aboutisse à des accords ou des transactions réussies. La société prévoit de maintenir la discrétion concernant le processus et n'informera des développements que si cela est légalement requis ou jugé approprié par le conseil d'administration.
MEI Pharma (Nasdaq: MEIP) hat die Engagement von Oppenheimer & Co. Inc. als seinen exklusiven Finanzberater bekannt gegeben, um bei der Bewertung strategischer Alternativen zu helfen. Dieser Schritt ist Teil des zuvor angekündigten Prozesses des Unternehmens zur Überprüfung potenzieller Optionen, wobei der Fokus auf der Maximierung des Aktionärswertes liegt. MEI Pharma betont, dass es keine Garantie dafür gibt, dass diese Erkundung zu Vereinbarungen oder erfolgreichen Transaktionen führen wird. Das Unternehmen plant, die Vertraulichkeit des Prozesses zu wahren und wird Entwicklungen nur offengelegen, wenn dies gesetzlich erforderlich ist oder vom Vorstand als angemessen erachtet wird.
- Engagement of a reputable financial advisor (Oppenheimer & Co. Inc.) to assist in strategic evaluation
- Focus on maximizing stockholder value
- Uncertainty regarding the outcome of the strategic alternatives review
- Potential for no successful agreements or transactions
There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.
About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a clinical-stage pharmaceutical company committed to developing novel and differentiated cancer therapies. We build our pipeline by acquiring promising cancer agents and creating value in programs through development, strategic partnerships, out-licensing and commercialization, as appropriate. Our approach to oncology drug development is to evaluate our drug candidates in combinations with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs to provide improved patient benefit. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 (“CDK9”) inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.
Forward-Looking Statements
Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation and the increase in interest rates as a result; potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812650753/en/
Justin J. File
858-898-0976
investor@meipharma.com
Source: MEI Pharma, Inc.
FAQ
What is the purpose of MEI Pharma's engagement with Oppenheimer & Co. Inc.?
Is MEI Pharma (MEIP) guaranteed to complete any transactions as a result of this strategic review?
Will MEI Pharma (MEIP) provide regular updates on the strategic alternatives review process?
What is the main goal of MEI Pharma's strategic alternatives review?
